CD68 and breast cancer: The balance of TILs may refine the predictive ability of the immune microenvironment, as CD4l°CD48l°CD8hi patients exhibited improved recurrence-free survival while the ratio of CD8+ T cells to CD68+ tumor associated macrophages predicted overall survival and response to neoadjuvant chemotherapy in breast cancer patients [3].